Evaluation of combined bevacizumab and intraperitoneal @entity3003 or @entity1311 therapy in a XXXX model of @entity43 .

@entity43 @entity19 @entity3003 @entity1311 @entity7173 @entity204
PURPOSE: To evaluate the pharmacokinetics of bevacizumab following @entity7173 and IV administration, and to investigate combined bevacizumab therapy ( @entity7173 or IV) with @entity7173 @entity1311 or @entity3003 in a @entity19 model of @entity43 . METHODS: Bevacizumab pharmacokinetics were investigated following IV or @entity7173 dosing, and @entity19 bearing peritoneal A2780 xenografts were treated with vehicle, IV or @entity7173 bevacizumab, @entity7173 @entity1311 , @entity7173 @entity1311 with co-administration of IV or @entity7173 bevacizumab, @entity7173 @entity3003 , and @entity7173 @entity3003 with co-administration of IV or @entity7173 bevacizumab. Survival time was defined as the time to @entity204 or the time to reach 120% of baseline body weight. RESULTS: Following @entity7173 administration, bevacizumab was rapidly absorbed and bioavailability was 92.8%. Median survival time, which was 33  days for control @entity19 , was increased by 24% with @entity7173 @entity1311 . @entity7173 @entity3003 failed to increase survival time when administered alone. IV and @entity7173 bevacizumab increased survival time by 42 and 33%. Combined bevacizumab and @entity7173 @entity1311 was superior to @entity1311 alone (P  =  0.01 for IV and P  =  0.04 for @entity7173 bevacizumab), and combined bevacizumab and @entity7173 @entity3003 was superior to @entity3003 alone (P  =  0.002 for IV and P  =  0.02 for @entity7173 bevacizumab). There were no significant differences in survival between groups receiving bevacizumab IV or @entity7173 , either alone (P  =  0.586), in combination with @entity1311 (P  =  0.467), or in combination with @entity3003 (P  =  0.149). CONCLUSIONS: Following @entity7173 administration to @entity19 , bevacizumab demonstrates rapid and near complete absorption. Bevacizumab therapy, initiated prior to @entity7173 @entity3003 or @entity1311 administration, increased survival time significantly in @entity19 , and results were not dependent on the route of bevacizumab administration (IV vs. @entity7173 ).
